Stocks · News reference
Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate
Revvity (NYSE:RVTY) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.22 by 15.57 percent. This is a 19.49 percent increase over earnings of $1.18 per share from the same
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135
RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.
Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126
Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.